Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557939 | 0.91 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL3558597 | 0.85 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL13098128 | 0.85 | SLC6A9 (0.72) | SLC6A9 | |
| SCHEMBL3569605 | 0.84 | SLC6A9 (0.85) | SLC6A9 | |
| SCHEMBL13037352 | 0.83 | SLC6A9 (0.77) | SLC6A9 | |
| SCHEMBL3885160 | 0.82 | SLC6A9 (0.84) | SLC6A9 | |
| SCHEMBL3042562 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL8244583 | 0.82 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL13714877 | 0.82 | SLC6A9 (0.64) | SLC6A9 | |
| SCHEMBL3567014 | 0.82 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1745018-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005110983-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110983-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | SLC1A2, SLC18A2, SLC1A1 | SLC6A9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.